Off-label use of eculizumab for neurological symptoms and progressive vision loss

Autor: Alicja Kuźniewska, Marta Jaskólska, Mariusz Kwarciany, Aleksandra Ciarka, Rafał Pęksa, Zbigniew Zdrojewski, Marcin Okrój
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Folia Neuropathologica, Vol 61, Iss 4, Pp 442-447 (2023)
Druh dokumentu: article
ISSN: 1641-4640
1509-572X
DOI: 10.5114/fn.2023.134313
Popis: We describe the results of eculizumab treatment of a patient with pachymeningitis, inflammatory infiltration of the left frontal lobe, and cerebral hematoma, who presented with progressive vision loss, epileptic seizures, and abnormal pattern of the complement system parameters. A 30-year-old female patient, initially diagnosed with hypereosinophilia and a tumour of the left orbit, developed a significant visual impairment in the left eye, progressive vision loss in the right eye, and neurological symptoms in the form of epileptic seizures and behavioural changes. Magnetic resonance imaging (MRI) revealed thickening of the dura mater in the left frontal area, slight oedema of the cortex, and subcortical white matter. Orbit biopsy showed non-specific inflammatory infiltrates. Despite the initial good response, symptoms progressed during treatment with glucocorticoids and immunosuppressants. Increased activity of the alternative complement pathway accompanied by a low level of its main inhibitor, factor H (FH), and the presence of anti-FH autoantibodies, was found. Genetic analysis revealed several missense variants of complement proteins, including two disease-linked mutations in FH (p.H402Y) and FI (T300A). An attempt to apply a complement C5 blocker, eculizumab, has been made. Neurological symptoms subsided, vision loss was inhibited, laboratory parameters improved, and discontinuation of steroid therapy was possible. The case underlines the role of complement system dysregulation in neurological distress.
Databáze: Directory of Open Access Journals
Externí odkaz: